tetano
Editor, Senior Moderator
Sci Rep
. 2024 May 29;14(1):12362.
doi: 10.1038/s41598-024-60297-y. Aripiprazole as protector against COVID-19 mortality
C Loucera-Muñecas[SUP] #[/SUP][SUP] 1 2 [/SUP], M Canal-Rivero[SUP] #[/SUP][SUP] 3 4 5 [/SUP], M Ruiz-Veguilla[SUP] 6 7 8 9 [/SUP], R Carmona[SUP] 1 2 [/SUP], G Bostelmann[SUP] 1 2 [/SUP], N Garrido-Torres[SUP] 6 7 8 [/SUP], J Dopazo[SUP] 1 2 10 11 [/SUP], B Crespo-Facorro[SUP] 6 7 8 9 [/SUP]
Affiliations
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79-0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein.
Keywords: Antipsychotics; COVID-19; Mortality; SARS-CoV-2.
. 2024 May 29;14(1):12362.
doi: 10.1038/s41598-024-60297-y. Aripiprazole as protector against COVID-19 mortality
C Loucera-Muñecas[SUP] #[/SUP][SUP] 1 2 [/SUP], M Canal-Rivero[SUP] #[/SUP][SUP] 3 4 5 [/SUP], M Ruiz-Veguilla[SUP] 6 7 8 9 [/SUP], R Carmona[SUP] 1 2 [/SUP], G Bostelmann[SUP] 1 2 [/SUP], N Garrido-Torres[SUP] 6 7 8 [/SUP], J Dopazo[SUP] 1 2 10 11 [/SUP], B Crespo-Facorro[SUP] 6 7 8 9 [/SUP]
Affiliations
- PMID: 38811612
- DOI: 10.1038/s41598-024-60297-y
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79-0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein.
Keywords: Antipsychotics; COVID-19; Mortality; SARS-CoV-2.